Mutational profile and analysis of lower-risk myelodysplastic syndromes (MDS) patients treated with luspatercept: Phase 2 pace-MDS study

Authors
Category Primary study
JournalBlood
Year 2017
This article has no abstract
Epistemonikos ID: f9527a45f2e9cda9ef9684795c496fa18738d866
First added on: Feb 08, 2025